In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Araclon Biotech S.L.

http://www.araclon.com/?lang=en

Latest From Araclon Biotech S.L.

After Solanezumab, What’s Next? Alzheimer’s Options Take The Stage At CTAD

Lilly will make its first presentation of solanezumab data from the recently failed Phase III EXPEDITION3 study during the Clinical Trials in Alzheimer’s Disease meeting where researchers will discuss amyloid beta and other hypotheses in Alzheimer’s disease Dec. 8-10 in San Diego.

Neurology Clinical Trials

Medical Device Deals Update, January 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, Alliance, and Financing activity.

Medical Device

Recent Tech Transfer Deals, January 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Tech Transfers Between Academia And Industry column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Pharmaceuticals, and Medical Devices sectors.

BioPharmaceutical Medical Device

Device/Diagnostics Quarterly Deal Statistics, Q1 2012

Medical device companies raised $1.1 billion, a 40% increase over Q4 2011’s $800 million. Two billion-dollar deals in the resuscitation market boosted device acquisition activity to $4.2 billion. Twenty diagnostics financings brought in a collective $302 million, soaring above the previous quarter’s $269 million. There were seven diagnostics M&A deals completed, totaling $589 million – down yet again.

Medical Device Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • Digital Imaging
UsernamePublicRestriction

Register